Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
Email Print Friendly Share
March 04, 2021 07:30 ET | Source: Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data
Reductions in HBsAg seen in both HBV DNA negative and HBV DNA positive subjects support a potential dosing schedule for AB-729 as infrequently as every 8 to 12 weeks
Several AB-729 Phase 2 proof-of-concept combination clinical trials expected to initiate this year
AB-836, Arbutus’ proprietary oral capsid inhibitor, on track to begin a Phase 1a/1b clinical trial in healthy volunteers and subjects with HBV in the first half of 2021
Conference Call and Webcast Scheduled Today at 8:45 AM ET作者: StephenW 时间: 2021-3-5 15:24